[1. Averhoff FM, Glass N, Holtzman D. Global Burden of Hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55(Suppl 1): 10-5.10.1093/cid/cis361]Open DOISearch in Google Scholar
[2. Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45:529-38.10.1016/j.jhep.2006.05.013]Open DOISearch in Google Scholar
[3. De Francesco R. Molecular virology of the hepatitis C virus. J Hepatol. 1999; 31(Suppl 1):47-53.10.1016/S0168-8278(99)80374-2]Open DOISearch in Google Scholar
[4. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot Ch, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994; 19:1321-4.10.1002/hep.1840190538]Open DOISearch in Google Scholar
[5. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42:962-73.10.1002/hep.20819]Open DOISearch in Google Scholar
[6. Caruntu FA, Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis. 2006; 15:249-56.]Search in Google Scholar
[7. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001; 33:321-7.10.1053/jhep.2001.22112]Open DOISearch in Google Scholar
[8. Koszinowski UH, Reddehase MJ, Jonjic S. The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol. 1991; 3:471-5.10.1016/0952-7915(91)90005-L]Search in Google Scholar
[9. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 1999; 30:595-601.10.1002/hep.51030031210462362]Open DOISearch in Google Scholar
[10. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Inter Med. 2000; 132:296-305.10.7326/0003-4819-132-4-200002150-0000810681285]Search in Google Scholar
[11. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 2003; 38: 4-13.10.1053/jhep.2003.5031012829979]Open DOISearch in Google Scholar
[12. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005; 25:7-17.10.1055/s-2005-86477815731994]Open DOISearch in Google Scholar
[13. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen ML, Shah NK, et al. IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003; 4:69-77.10.1038/ni87512483210]Open DOISearch in Google Scholar
[14. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko, SV, MacDonald MR, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131:1887-98.10.1053/j.gastro.2006.09.05217087946]Search in Google Scholar
[15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801.10.1038/nature08463317200619759533]Search in Google Scholar
[16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399-401.10.1038/nature0830919684573]Search in Google Scholar
[17. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Vir Hepat. 2012; 19:173-81.10.1111/j.1365-2893.2011.01497.x22329371]Open DOISearch in Google Scholar
[18. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012; 9: 406-417.10.1038/nrgastro.2012.10122641049]Open DOISearch in Google Scholar
[19. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138:1338-45.10.1053/j.gastro.2009.12.05620060832]Search in Google Scholar
[20. Thompson JA. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012; 142:1335-9.10.1053/j.gastro.2012.01.04622537440]Search in Google Scholar
[21. Tanaka Y, Nishida Y, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41:1105-9.10.1038/ng.44919749757]Open DOISearch in Google Scholar
[22. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41:1100-4.10.1038/ng.44719749758]Open DOISearch in Google Scholar
[23. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012; 26:401-12.10.1016/j.bpg.2012.09.00923199500]Open DOISearch in Google Scholar
[24. Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH. Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-α plus ribavirin: A meta-analysis. Gene. 2012; 507:27-35.10.1016/j.gene.2012.07.02622842190]Search in Google Scholar
[25. Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012; 19:677-84.10.1111/jvh.1200322967098]Open DOISearch in Google Scholar
[26. Thompson AJ, McHutchinson JG. Will IL28B polymorphism remain relevant in the era of directacting antiviral agents for hepatitis C virus? Hepatology. 2012; 56:373-81.10.1002/hep.2579222511355]Open DOISearch in Google Scholar
[27. King LY, Chung RT. IL28B testing in a rapidly changing world: Still relevant? J Hepatol. 2013; 58:847-9.10.1016/j.jhep.2013.02.00223416431]Open DOISearch in Google Scholar
[28. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1195-206.10.1056/NEJMoa1010494376684921449783]Search in Google Scholar
[29. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1207-17.10.1056/NEJMoa1009482315312521449784]Search in Google Scholar
[30. Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405-16.10.1056/NEJMoa101291221696307]Search in Google Scholar
[31. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417-28.10.1056/NEJMoa101308621696308]Search in Google Scholar
[32. Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz E, Roberts S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013; 58:883-9.10.1016/j.jhep.2012.12.02323321318]Open DOISearch in Google Scholar
[33. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013; 368:45-53.10.1056/NEJMoa120880923281975]Search in Google Scholar
[34. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368:34-44.10.1056/NEJMoa120895323281974]Search in Google Scholar
[35. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatmentexperienced chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17, 65-76.10.3111/13696998.2013.86003324160335]Open DOISearch in Google Scholar
[36. Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17:77-87.10.3111/13696998.2013.84415924032626]Open DOISearch in Google Scholar
[37. Stedman C. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013; 28:38-45.10.1111/jgh.1202823137126]Open DOISearch in Google Scholar
[38. You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013; 14:2581-9.10.1517/14656566.2013.85007424138198]Search in Google Scholar
[39. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012; 56:1247-53.10.1016/j.jhep.2011.12.03322326470]Search in Google Scholar
[40. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with different expression of intrahepatic interferon stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52:1888-96.10.1002/hep.23912365330320931559]Open DOISearch in Google Scholar
[41. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45:164-71.10.1038/ng.2521379339023291588]Open DOISearch in Google Scholar
[42. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med. 2013; 10:1109-16.10.1084/jem.20130012367470423712427]Open DOISearch in Google Scholar
[43. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-G allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014; 209:350-4.10.1093/infdis/jit433388316223956438]Search in Google Scholar
[44. Stattermayer AF, Strassl R, Maieron A, Rutter K, Strauber R, Strasser M, et al. Polymorphisms of interferon-l4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39:104-11. 10.1111/apt.1254724205831]Search in Google Scholar